Friday, Nov 9, 2018
News Recap:
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program.
High Prevalence of Cirrhosis in Adults with Chronic...
SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa
Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.
The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck’s patent was invalid. He said it did not meet a requirement that it disc
Friday, September 22, 2017
News Recap:
Access to Treatment:
This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad). Imagine being sick or on treatment in one of these stricken areas!
In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...
– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for Chronic Hepatitis C Virus Infection –
MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...
Friday, July 14, 2017
News Recap
Local
New measures boost addiction treatment access in Victoria
New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilea
3-drug mixture was nearly 100 percent effective in drug company trials
WEDNESDAY, May 31, 2017 (HealthDay News) -- A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report.
The pill -- which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir -- was nearly 100 percent effective in curing hepatitis C in patients whose disease retu...
California-headquartered Gilead Sciences has warned against the use of generic versions of its blockbuster Hepatitis C drugs procured by patients directly through “buyers clubs.” A disruptive phenomenon, dozens of buyers clubs have mushroomed in recent years that enable supply of generic lifesaving medicines to thousands of patients afflicted with the fatal liver ailment.
In its latest May 9 regulatory filings in Form 10K at the US Securities Exchange Com
Friday, April 7, 2017
News Recap
Canada
Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...
